## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no methods, figures, tables, or supplementary materials were provided
- **Shared manuscript claim summary** The authors present a deep learning model that predicts islet enhancer activity and uses sequence variant effect predictions to prioritize candidate causal variants at T2D and glycemic trait loci. They report that the model learns islet-specific transcription factor regulatory patterns, nominates a single causal variant at 101 genetic signals, includes three variants with prior reporter activity evidence, and that biochemical testing in a beta cell line supports the model-prioritized variant at one additional signal. The model and scores for approximately 67 million variants are publicly distributed.
- **Visible evidence base** Abstract text only; no figures, tables, methods, or supplementary data were supplied
- **Missing materials affecting confidence** Full manuscript, methods description, model architecture and training details, validation metrics, variant prioritization criteria, fine-mapping details, biochemical assay protocols, and all quantitative results

## Reviewer
- **Overall assessment** The abstract describes a potentially useful deep learning approach for islet enhancer variant prioritization, with a plausible conceptual basis and a clear translational goal. However, the provided material is insufficient to evaluate the technical validity, reproducibility, or robustness of the claims. Several statements are broad and lack quantitative support. The work may be of interest to the diabetes genetics and regulatory genomics communities, but the case is not established from the abstract alone.
- **Who would be interested in the results, and why** Geneticists studying type 2 diabetes and glycemic traits, researchers developing or applying deep learning methods for noncoding variant interpretation, and experimentalists seeking prioritized variants for functional validation in pancreatic islets or beta cells.
- **Major strengths** The focus on pancreatic islets as a disease-relevant tissue is appropriate. The combination of deep learning with biochemical validation in a relevant cell line is a strong design element. Public distribution of model and scores is a practical contribution.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Technical soundness
  - **Claim pointer** The model "learns islet-specific TF regulatory patterns" and "can be used to prioritize candidate causal variants."
  - **Evidence pointer** Abstract only; location not provided
  - **Concern** No details are given on model architecture, training data, validation strategy, or performance metrics. The claim of learning islet-specific regulatory patterns requires demonstration of specificity against other tissues or cell types, which is not described.
  - **Why it matters** Without evidence of model accuracy and specificity, the prioritization results cannot be interpreted as reliable. The central utility of the method depends on its predictive performance.
  - **Resolution test** Provide model architecture, training and test datasets, performance metrics (e.g., AUROC, AUPRC) against held-out enhancer data, and comparisons to non-islet models or tissues to demonstrate islet specificity.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Evidence strength
  - **Claim pointer** "At 101 genetic signals ... our method nominates a single causal variant for each association signal."
  - **Evidence pointer** Abstract only; location not provided
  - **Concern** The abstract does not state how the 101 signals were selected, how linkage disequilibrium was defined, what criteria were used to nominate a single variant, or whether this nomination was validated against any gold standard. The inclusion of three variants with prior reporter activity is noted, but the proportion of signals with any external validation is unclear.
  - **Why it matters** The claim of nominating a single causal variant per signal is strong and implies a high level of precision. Without a clear selection and validation framework, the reader cannot assess whether this is a meaningful improvement over existing methods or a result of arbitrary thresholds.
  - **Resolution test** Specify the selection criteria for the 101 signals, the LD threshold, the nomination rule, and provide a comparison to existing prioritization methods or to fine-mapping posterior probabilities.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Reproducibility
  - **Claim pointer** "We biochemically test all candidate causal variants from statistical fine-mapping using a pancreatic islet beta cell line and show biochemical evidence of allelic effects on TF binding for the model-prioritized variant."
  - **Evidence pointer** Abstract only; location not provided
  - **Concern** The abstract does not describe the biochemical assay, the number of variants tested, the number of replicates, the effect size, or the statistical significance of the allelic effect. It is unclear whether the result is a single observation or a robust finding.
  - **Why it matters** Biochemical validation is a key strength of the study, but without quantitative details the reader cannot judge the reliability or generalizability of the finding.
  - **Resolution test** Provide assay type, number of variants and replicates, effect sizes, statistical tests, and confidence intervals for the allelic effect.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Clarity
  - **Affected element** "islet enhancer perturbation scores across ~67 million genetic variants"
  - **Evidence pointer** Abstract only; location not provided
  - **Issue** The term "perturbation scores" is not defined. It is unclear whether these are predicted effect sizes, allelic fold changes, or some other metric.
  - **Required correction** Define the score type and the interpretation of its magnitude in the abstract or methods.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Completeness
  - **Affected element** "three variants previously shown to alter reporter activity in islet-relevant cell types"
  - **Evidence pointer** Abstract only; location not provided
  - **Issue** The abstract does not state whether these three variants were among the 101 signals or whether they were used as a validation set.
  - **Required correction** Clarify the relationship between these three variants and the 101 signals, and specify whether they were part of the training or validation process.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Generalizability
  - **Affected element** "deep learning methods like the one presented in this study will enhance the prioritization of candidate causal variants"
  - **Evidence pointer** Abstract only; location not provided
  - **Issue** This statement is speculative and not directly supported by the presented results.
  - **Required correction** Soften the claim or provide comparative data showing improvement over existing methods.
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria**  
  Originality: The approach is not clearly novel relative to existing deep learning enhancer models, but the islet focus and integration with fine-mapping may offer a new application.  
  Scientific importance: The problem of causal variant prioritization in T2D is important, and a reliable method would be valuable.  
  Interdisciplinary readership: The work bridges computational genomics and diabetes biology, which could attract a broad audience.  
  Technical soundness: Not assessable from the abstract; major details are missing.  
  Readability for nonspecialists: The abstract is generally clear, but terms like "perturbation scores" and "fine-mapping" may need brief explanation for a general audience.
- **Recommendation posture** Currently not established from the provided evidence. The abstract suggests a potentially useful contribution, but the technical and validation details are insufficient to support the claims. A full manuscript with methods and results would be required for a substantive evaluation.

## Risk / unsupported claims
- The claim that the model "learns islet-specific TF regulatory patterns" is unsupported without comparative or ablation data.
- The claim of nominating a single causal variant at 101 signals is unsupported without selection criteria and validation.
- The biochemical evidence for allelic effects is unsupported without quantitative assay details.
- The general statement that deep learning methods "will enhance" prioritization is speculative and not directly evidenced.